Keyword: Alnylam Pharmaceuticals

The Medicines Company reported that its PCSK9 drug, inclisiran, cut "bad" LDL cholesterol in patients with plaque buildup in their arteries.

The arrival of the ex-Alnylam VP is one of several changes at the top of Synlogic’s medical, regulatory and financial departments.

Medicines Company showed its siRNA inclisiran has a clean safety profile and is as effective as incumbent drugs sold by Amgen, Regeneron and Sanofi.

Medicines Company is yet to share the efficacy data that will show whether inclisiran can compete but has sought to tackle lingering safety concerns.

Biotech leaders criticized the dismissals of Chinese scientists from U.S. universities in a letter with more than 150 signatures.

Outgoing BIO Chair John Maraganore and his successor, Jeremy Levin, reflected on drug pricing, its drivers and its place in the innovation ecosystem.

CEOs weigh in on increasingly large biotech IPOs and an increase in companies going public at earlier stages.

The Medicines Company announced long-term data for inclisiran, showing that the drug lowered “bad” LDL cholesterol by more than 50%.

Over the past year, Sanofi and Alnylam have been retooling their 2014 R&D pact around Alnylam's RNA tech; today, the pair signaled its end.

Alnylam's givosiran reduced the rate of porphyria attacks in patients with acute hepatic porphyria. The company will file a rolling NDA for givosiran in mid-2019.